NOVAST LABS LTD
GenericsNOVAST LABS LTD is a generic drug manufacturer focused on Dermatology, Cardiovascular, Neurology.
NOVAST LABS LTD's Key Drugs
NOVAST LABS LTD's core commercial portfolio centers on CONJUGATED ESTROGENS, MELAMISA, YAELA, spanning Dermatology and Cardiovascular — its most strategically important drugs approved in the last 15 years.
Vasomotor Symptoms
Premenstrual Dysphoric Disorder
Premenstrual Dysphoric Disorder
Premenstrual Dysphoric Disorder
Prevention of Pregnancy
NOVAST LABS LTD's Recent FDA Approvals
New NDA/BLA approvals for NOVAST LABS LTD over the last two years — novel drugs only, excluding generics and label supplements.
NOVAST LABS LTD's Therapeutic Areas
NOVAST LABS LTD's approved drugs and pipeline span 5 therapeutic areas, led by Dermatology and Cardiovascular, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
NOVAST LABS LTD's Top Competitors
NOVAST LABS LTD's closest competitors by therapeutic-area and drug-target overlap include Bayer, Pfizer, and OTSUKA. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
NOVAST LABS LTD Pipeline Snapshot
Active clinical trials for NOVAST LABS LTD across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • CONJUGATED ESTROGENS leads revenue
- • 5 key drugs tracked
Trial Catalysts
- • Dermatology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (25)
Discontinued (0)
Company Info
- First Approval
- 2010-12-29
- Latest
- 2025-10-28
- Applications
- 53